Incretin Atlas › Trials › evoke / evoke+
evoke / evoke+
Semaglutide · Early Alzheimer's disease
Design
- Molecule(s)
- Semaglutide
- Population
- Early Alzheimer's disease
- Official title
- A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Registry status
- completed · 2021-05 → 2025-09
- Participants
- 3680
- Duration
- 104 weeks
- Registry
- NCT04777396, NCT04777409
Outcomes in the indication
evoke / evoke+ Semaglutide · Early Alzheimer's disease · 104 weeks · n = 3680 seed
Primary endpoint (CDR-SB) not met (announced Nov 2025)
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| CDR-SB, change from baseline evoke week 104 | +2.3 | +2.3 | −0.1 (−0.3 to +0.2) points (0-18) | verified |
| CDR-SB, change from baseline evoke+ week 104 | +2.2 | +2.1 | +0.1 (−0.2 to +0.4) points (0-18) | verified |
Verbatim quotes (2)
- CDR-SB, change from baseline
mean changes in CDR-SB score from baseline to week 104 were 2·3 (SE 0·1) and 2·2 (0·1) with semaglutide, compared with 2·3 (0·1) and 2·1 (0·1) with placebo (estimated difference -0·08 [95% CI -0·35 to 0·20], p=0·57 in evoke and 0·10 [-0·17 to 0·38], p=0·46 in evoke+)
- CDR-SB, change from baseline
mean changes in CDR-SB score from baseline to week 104 were 2·3 (SE 0·1) and 2·2 (0·1) with semaglutide, compared with 2·3 (0·1) and 2·1 (0·1) with placebo (estimated difference -0·08 [95% CI -0·35 to 0·20], p=0·57 in evoke and 0·10 [-0·17 to 0·38], p=0·46 in evoke+)
Related registry entries
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| evoke / evoke+ A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) | Alzheimer's | Phase 3 | completed | 2021-05 → 2025-09 | 1840 | CDR-SB primary endpoint not met | NCT04777396 |
| EVOKE Plus A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) | Alzheimer's | Phase 3 | completed | 2021-05 → 2025-09 | 1840 | CDR-SB primary endpoint not met (with evoke) | NCT04777409 |
Primary sources
- Novo Nordisk A/S. A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE) (EVOKE). ClinicalTrials.gov identifier NCT04777396. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04777396
- Novo Nordisk A/S. A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE Plus) (EVOKE Plus). ClinicalTrials.gov identifier NCT04777409. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04777409
- Cummings JL, Atri A, Sano M, Zetterberg H, Scheltens P, Knop FK, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet. 2026;407(10544):2167-2179. PMID: 41865758.
How to cite this page
Medical Adviser's Group. Incretin Atlas: evoke / evoke+. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/evoke-evoke/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.